Vktx nasdaq.

Viking Therapeutics (NASDAQ:VKTX) shares gained over 5% in extended trading on Monday after the drugmaker reported positive findings from an ongoing study of its lead drug candidate, VK2809.VK2809 ...VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 94% based on the firm’s underlying fundamentals and the stock ...VKTX Price Action: Viking Therapeutics is making new 52-week highs on Monday. The stock was up 46.2% at $5.88 at time of publication, according to Benzinga Pro. Photo: Konstantin Kolosov from Pixabay.Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 94% based on the firm’s underlying fundamentals and the stock ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 74% of the company.May 11, 2023 · As of May 11, 2023, the average one-year price target for Viking Therapeutics is 29.89. The forecasts range from a low of 23.23 to a high of $36.75. The average price target represents an increase ...

The latest price target for . Viking Therapeutics (NASDAQ: VKTX) was reported by Truist Securities on Monday, October 2, 2023.The analyst firm set a price target for 32.00 expecting VKTX to rise ...Viking Therapeutics last announced its quarterly earnings data on October 25th, 2023. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.01. Viking Therapeutics has generated ($0.93) earnings per share over the last year ( ($0.93) diluted earnings per share).

Today's Change. (1.85%) $0.21. Current Price. $11.56. Price as of November 22, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium ...Find the latest SEC Filings data for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.NASDAQ Stock VKTX - Share Viking Therapeutics, Inc. trades in NASDAQ under Health Care Deals in Major Pharmaceuticals. These tomorrow's movement predictions & forecast of Viking Therapeutics, Inc. (VKTX) are just for tomorrow's session.Shares of the clinical-stage metabolic disorder specialist Viking Therapeutics ( VKTX 7.03%) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's shares are ...The 36-month beta value for VKTX is also noteworthy at 0.59. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.” ... Viking Therapeutics Inc (NASDAQ: VKTX)’s stock price has plunge by 0.94relation to previous closing price ...

Find the latest press releases from Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.

Dec 1, 2023 · 9 brokers have issued 1 year target prices for Viking Therapeutics' shares. Their VKTX share price targets range from $19.00 to $37.00. On average, they predict the company's stock price to reach $30.25 in the next twelve months. This suggests a possible upside of 132.5% from the stock's current price.

Research Viking Therapeutics' (Nasdaq:VKTX) stock key valuation metrics while comparing it with its industry peers & market side by side. Dashboard Markets Discover Watchlist Portfolios Screener Viking Therapeutics, Inc.NASDAQ: VKTX Viking Therapeutics. Market Cap. $1B. Today's Change (1.85%) $0.21. Current Price. $11.56. ... (VKTX 1.85%) are down about 25% from the peak they reached in mid-March. If you weren't ...Viking Therapeutics, Inc. (VKTX-NASDAQ) announced the presentation of data from a proof of concept a 35.7% mean reduction in liver weight. The company is On September 11, 2017, Viking announced positive results from clinical trial of patients with Current Price (09/12/17) $1.16 Valuation $7.00 OUTLOOK SUMMARY DATA Risk Level …Viking Therapeutics (NASDAQ:VKTX) is arguably best known for being one of the frontrunners to win the "NASH Dash," i.e. the first company to secure approval to market and sell a drug designed to ...NAV / 1-Day Return 392.46 / 0.42 %. Total Assets 2.7 Bil. Adj. Expense Ratio 0.080%. Expense Ratio 0.080%. Distribution Fee Level Low. Share Class Type Institutional. Category Large Blend ...

Viking Therapeutics, Inc. Common Stock (VKTX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.NASDAQ: VKTX Viking Therapeutics. Market Cap. $1B. Today's Change (1.85%) $0.21. Current Price. $11.56. ... (VKTX 1.85%) are down about 25% from the peak they reached in mid-March. If you weren't ...Viking Therapeutics, Inc. Common Stock (VKTX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Maybe you’ve never invested before. Maybe you have no clue what the difference is between NASDAQ and the New York Stock Exchange. Regardless, the name Charles Schwab probably rings a bell.Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Viking Therapeutics Inc (Symbol: VKTX), where a total of 11,518 contracts have traded ...Dec 4, 2023 · Viking Therapeutics Inc (NASDAQ:VKTX)’s Major holders. Insiders own 5.89% of the company shares, while shares held by institutions stand at 68.75% with a share float percentage of 73.05%. Investors are also buoyed by the number of investors in a company, with Viking Therapeutics Inc having a total of 246 institutions that hold shares in the ... SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...

Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP agonist compound VK2735 for the ...

Viking Therapeutics Inc (Symbol: VKTX) saw options trading volume of 5,067 contracts, representing approximately 506,700 underlying shares or approximately 53.5% of VKTX's average daily trading ...The Nasdaq Composite ... (VKTX 6.23%), whose shares jumped 48%. Viking is looking at a NASH treatment that could use an approach similar to that of Madrigal's candidate, and while Viking's drug is ...VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 83% based on the firm’s underlying fundamentals and the stock ...SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Viking Therapeutics Inc (NASDAQ:VKTX) 13.01 Delayed Data As of Dec 01 +0.79 / +6.42% Today’s Change 3.54 Today ||| 52-Week Range 25.72 +38.35% Year-to-Date Quote Profile News Charts Forecasts...Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2023 Earnings Conference Call April 26, 2023 4:30 PM ETCompany Participants. Stephanie Diaz - Manager of Investor Relations. Brian Lian - Viking’s ...VFS. VinFast Auto Ltd. Ordinary Shares. $17.15 -0.84 -4.67%. Find the latest news headlines from Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.

Nasdaq | VKTX U.S.: Nasdaq Viking Therapeutics Inc. Watch NEW Set a price target alert After Hours Last Updated: Dec 1, 2023 7:47 p.m. EST Delayed quote $ 13.10 0.09 0.69% …

May 18, 2023 · NASDAQ: VKTX Viking Therapeutics. Market Cap. $1B. Today's Change (-2.28%) -$0.28. ... (VKTX-2.28%) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's ...

The latest price target for Viking Therapeutics (NASDAQ: VKTX) was reported by Truist Securities on December 4, 2023.The analyst firm set a price target for $32.00 expecting VKTX to rise to within ...He does not neglect the obesity-centered candidate VK2735, however, and writes, “We view VKTX’s lead candidate THR-β agonist VK2809 for NASH as similar to Madrigal Pharmaceutical’s MGL-3196 ...Find the latest Madrigal Pharmaceuticals, Inc. (MDGL) stock quote, history, news and other vital information to help you with your stock trading and investing.Standing squarely in the bull camp, BTIG analyst Justin Zelin rates VKTX a Buy along with a $20 price target. This target puts the upside potential at a whopping 221%. This target puts the upside ...Please enter a valid Stock, ETF, Mutual Fund, or index symbol. Recent research: Viking Therapeutics Inc. Viking Therapeutics Inc VKTX:NASDAQ. Last Price ...Dec 1, 2023 · View Viking Therapeutics, Inc VKTX investment & stock information. Get the latest Viking Therapeutics, Inc VKTX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. At Stock Options Channel, our YieldBoost formula has looked up and down the VKTX options chain for the new August 11th contracts and identified one put and one call contract of particular interest ...The 36-month beta value for VKTX is also noteworthy at 0.59. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.” ... Viking Therapeutics Inc (NASDAQ: VKTX)’s stock price has plunge by 0.94relation to previous closing price ...VKTX data by YCharts. Which low-priced healthcare stocks might be the next big movers? Wall Street analysts think Agenus ( AGEN 1.60% ) and Aclaris Therapeutics ( ACRS 3.01% ) could deliver market ...

Viking Therapeutics, Inc (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today ...VKTX Stock 12 Months Forecast. $34.00. (187.40% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $34.00 with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 187.40% change from the last price of $11.83. Rhumbline Advisers acquired a new position in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 127,829 shares of the biotechnology company’s stock, valued at approximately $2,072,000. Rhumbline …Instagram:https://instagram. cash app stock marketmoderna ceoaclly stockmonthly dividend reits Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. Return. ... VKTX. $12.01 (-2.24%) $0.28 *Average returns of all recommendations since inception. Cost basis and ... intercept nashtarget bk Find the latest Earnings Report Date for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com. whitneyhancock Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and …12.28 USD. +6.23%. +8.96%. +30.64%. Nov. 14. Viking Therapeutics' Phase 2b of VK2809 to Treat Non-Alcoholic Steatohepatitis Meets Primary Endpoint; Shares Rise Early. MT. …Apr 4, 2023 · Find out why VKTX stock is a Buy. ... (NASDAQ:VKTX). As you know, Viking shares recently rallied over 60% in a single trading session due to its positive early obesity data. Though Viking executed ...